Income StatementBalance SheetCash FlowSegments
Johnson & Johnson logo

Johnson & Johnson Business Segments

Business, geographic, and product segment breakdowns

Johnson & Johnson generates $96.4B in annual revenue across 3 key segments: ELECTROPHYSIOLOGY ($5.6B), other cardiovascular ($397.0M), and SPINE,SPORTS & OTHER ($2.9B). Based on the Q1 2026 filing.

ELECTROPHYSIOLOGY (TTM)$5.6Bother cardiovascular (TTM)$397.0MSPINE,SPORTS & OTHER (TTM)$2.9B
Latest FilingQ1 2026
Report Date2026-04-22
Market Cap$564.11B
P/E Ratio26.81
ROE26.42%

Products & Services

% Change

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
ELECTROPHYSIOLOGY3.1%1.8%1.8%1.8%1.8%—
other cardiovascular1.7%1.1%1.1%1.1%1.1%—
SPINE,SPORTS & OTHER-0.2%-0.6%-0.6%-0.6%-0.6%—

Sales to Customers

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
ELECTROPHYSIOLOGY$1.3B$1.4B$1.4B$1.4B$1.4B—
other cardiovascular$95.0M$99.3M$99.3M$99.3M$99.3M—
SPINE,SPORTS & OTHER$731.5M$713.0M$713.0M$713.0M$713.0M—

Percent Change (as a percent)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
RYBREVANT + LAZCLUZE———99.7%—82.7%
TALVEY—48.4%55.0%60.8%6.0%76.7%
Tremfya—18.2%31.0%41.3%9.5%68.3%
CARVYKTI8.4%——83.5%6.3%62.1%
STELARA-3.4%-33.7%-42.7%-41.3%-1.8%-59.7%
SPRAVATO—41.9%53.3%61.5%4.4%46.4%
Tecvayli—13.3%23.1%31.3%—33.5%
Other-0.2%-7.2%-16.9%-13.1%—-27.8%
ERLEADA—11.9%23.4%18.4%1.2%23.1%
DARZALEX0.5%20.3%23.0%21.7%1.3%22.5%
OPSUMIT/OPSYNVI—-0.5%6.4%-0.8%—16.1%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA0.8%-14.5%-5.9%-11.3%—15.0%
EDURANT/rilpivirine—10.7%21.6%16.4%0.8%14.1%
Other Oncology-96.8%21.7%11.7%9.7%4.5%-10.6%
OTHER INFECTIOUS DISEASES-13.0%-47.6%-79.8%-17.5%—-10.4%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA—-3.7%-9.4%-11.6%—10.0%
SURGICAL2.9%3.7%9.9%14.9%0.8%9.7%
Remicade-1.2%7.5%15.9%13.6%—-9.5%
CONCERTA/Methylphenidate—-16.3%0.2%-1.4%-2.7%-8.0%
TRAUMA0.2%0.9%1.2%4.2%1.1%8.0%
KNEES—-3.0%-1.1%7.0%2.0%7.9%
UPTRAVI—-3.6%11.7%5.6%0.4%7.1%
XARELTO8.1%33.3%5.6%7.4%—-7.0%
IMBRUVICA-0.1%-9.5%-4.5%-7.8%—-6.9%
HIPS—-3.1%1.0%6.4%0.8%6.5%
CONTACT LENSES / OTHER1.7%1.0%5.1%5.2%1.0%5.5%
OTHER NEUROSCIENCE-4.4%-19.6%-8.4%-8.9%—-5.4%
GENERAL-0.2%-0.5%3.3%3.9%1.5%4.9%
ADVANCED—-1.2%2.0%5.0%0.1%4.6%
SPINE & OTHER—-10.8%-2.1%0.3%—3.5%
SIMPONI / SIMPONI ARIA—18.9%28.6%32.9%—-1.7%
CAPLYTA0.0%0.0%0.0%0.0%0.0%0.0%

Sales to customers (Note 9)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
DARZALEX$3.1B$3.2B$3.5B$3.7B$3.9B$4.0B
Other$281.0M$2.8B$309.0M$264.0M$249.0M$2.9B
Tremfya$949.0M$956.0M$1.2B$1.4B$1.6B$1.6B
GENERAL$1.4B$1.3B$1.4B$1.4B$1.5B$1.4B
ADVANCED$1.2B$1.1B$1.2B$1.2B$1.2B$1.1B
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA$1.1B$903.0M$992.0M$929.0M$986.0M$1.0B
CONTACT LENSES / OTHER$937.0M$919.0M$965.0M$1.0B$1.0B$969.0M
ERLEADA$784.0M$771.0M$908.0M$936.0M$959.0M$949.0M
TRAUMA$764.0M$772.0M$768.0M$793.0M$813.0M$833.0M
SPINE & OTHER—$671.0M$727.0M$698.0M—$694.0M
IMBRUVICA$731.0M$709.0M$735.0M$695.0M$684.0M$660.0M
STELARA$2.3B$1.6B$1.7B$1.6B$1.2B$656.0M
SIMPONI / SIMPONI ARIA$583.0M$659.0M$690.0M$687.0M$632.0M$647.0M
XARELTO$676.0M$690.0M$621.0M$635.0M$687.0M$642.0M
OPSUMIT/OPSYNVI—$522.0M$582.0M$578.0M—$606.0M
CARVYKTI$334.0M$369.0M$439.0M$524.0M$555.0M$597.0M
UPTRAVI$465.0M$451.0M$476.0M$484.0M$491.0M$483.0M
SPRAVATO$297.0M$320.0M$414.0M$459.0M$503.0M$468.0M
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA$407.0M$403.0M$396.0M$397.0M$383.0M$443.0M
HIPS$418.0M$409.0M$421.0M$405.0M$439.0M$436.0M
Remicade$359.0M$467.0M$455.0M$476.0M$370.0M$422.0M
KNEES$398.0M$389.0M$389.0M$377.0M$432.0M$420.0M
EDURANT/rilpivirine$322.0M$358.0M$360.0M$385.0M$383.0M$409.0M
SURGICAL$365.0M$361.0M$403.0M$383.0M$411.0M$396.0M
CAPLYTA$0.0$0.0$211.0M$240.0M$249.0M$270.0M
OTHER NEUROSCIENCE$255.0M$277.0M$270.0M$256.0M$245.0M$262.0M
RYBREVANT + LAZCLUZE$122.0M$141.0M$179.0M$198.0M$216.0M$257.0M
Tecvayli$146.0M$151.0M$166.0M$177.0M$176.0M$202.0M
Other Oncology$75.0M$214.0M$93.0M$94.0M$100.0M$192.0M
TALVEY$85.0M$86.0M$106.0M$122.0M$149.0M$152.0M
CONCERTA/Methylphenidate$159.0M$148.0M$164.0M$140.0M$132.0M$136.0M
OTHER IMMUNOLOGY$0.0$1.0M$8.0M$12.0M$40.0M$46.0M
OTHER INFECTIOUS DISEASES$45.0M$41.0M$47.0M$47.0M$40.0M$37.0M

Discount rate

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
HLD-0117————17.5%—
HLD-0915————17.0%—

Probability of success factor

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
HLD-0117————$0.2—
HLD-0915————$0.7—

Selling, marketing and administrative expenses

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Shipping and Handling$225.0M$225.0M$225.0M$225.0M$225.0M—

Geographic

Long-Lived Assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Asia-Pacific, Africa$1.5B———$1.5B—
Europe$27.3B———$28.0B—
Western Hemisphere excluding U.S.$1.7B———$2.2B—

Percent Change

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Europe—-1.0%3.3%10.7%—14.5%
Western Hemisphere, excluding U.S.—-2.3%-0.5%4.9%—10.8%
Asia-Pacific, Africa—-2.8%4.4%4.0%—8.5%
United States—5.9%7.8%6.2%—8.3%

Sales to customers (Note 9)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
United States$13.2B$12.3B$13.5B$13.7B$14.2B$13.3B
Europe$4.9B$5.1B$5.4B$5.4B$5.6B$5.8B
Asia-Pacific, Africa$3.3B$3.3B$3.6B$3.6B$3.5B$3.6B
Western Hemisphere, excluding U.S.$1.1B$1.2B$1.2B$1.2B$1.3B$1.3B

Percent Change (as a percent)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
United States0.6%5.9%7.8%6.2%0.3%8.3%

Business Segments

Additions to Property, Plant & Equipment

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
MEDTECH$814.0M$480.0M$591.0M$603.0M$827.0M$509.0M
Innovative Medicine$739.0M$276.0M$411.0M$479.0M$910.0M$508.0M
General Corporate$59.0M$39.0M$41.0M$75.0M$100.0M$32.0M
Consumer Health$0.0$0.0$0.0$0.0$0.0—

Depreciation and Amortization

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Innovative Medicine$967.0M$884.0M$1.0B$832.0M$1.0B$1.0B
MEDTECH$867.0M$836.0M$842.0M$886.0M$926.0M$903.0M
General Corporate$62.0M$52.0M$60.0M$59.0M$70.0M$65.0M
Consumer Health$0.0$0.0$0.0$0.0$0.0—

Total Assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
MEDTECH$84.3B$85.1B$86.7B$86.5B$86.5B$86.2B
Innovative Medicine$57.1B$58.7B$75.5B$74.4B$78.1B$78.1B
General Corporate$38.7B$49.8B$31.2B$31.9B$34.7B$36.6B

Litigation expense

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
General Corporate—————$300.0M

Long-Lived Assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
General Corporate$1.2B———$1.2B—

Adjustments To Revenue Recognized, Percent

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Innovative Medicine—4.6%———4.7%

Amortization

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Innovative Medicine—$600.0M$800.0M$600.0M—$800.0M
MEDTECH—$500.0M$500.0M$500.0M—$500.0M

Cost of products sold

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Innovative Medicine$3.5B$4.0B$4.0B$3.7B$4.0B$4.4B
MEDTECH$3.6B$3.3B$3.6B$3.6B$4.0B$3.7B

Currency translation/Other

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Innovative Medicine-$440.0M$215.0M$543.0M$0.0$57.0M-$155.0M
MEDTECH-$181.0M$82.0M$230.0M$0.0$25.0M-$59.0M

Goodwill (Note 3)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
MEDTECH$33.5B$33.6B$33.8B$33.8B$33.8B$33.7B
Innovative Medicine$10.7B$10.9B$14.3B$14.3B$15.0B$14.8B

Goodwill, related to acquisitions

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Innovative Medicine$20.0M$0.0$2.9B$0.0$642.0M$0.0
MEDTECH$2.0M$0.0$0.0$0.0$0.0$0.0

Goodwill, Written off Related to Sale of Business Unit

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Innovative Medicine$0.0$0.0$0.0$0.0$0.0$0.0
MEDTECH—$29.0M———$0.0

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Innovative Medicine$4.0B$5.2B$5.6B$6.4B$5.1B$5.3B
MEDTECH$72.0M$1.4B$1.2B$1.3B$201.0M$1.2B

Other (income) expense, net

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
MEDTECH$84.0M-$60.0M$190.0M$2.0M$806.0M$76.0M
Innovative Medicine-$201.0M-$166.0M$14.0M-$368.0M-$193.0M-$12.0M

Percent Change (as a percent)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Innovative Medicine-9.2%22.3%24.0%21.3%0.9%32.0%
MEDTECH0.8%16.4%23.5%21.2%—18.5%

Research and development expense

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Innovative Medicine$3.7B$2.5B$2.9B$2.9B$3.5B$2.8B
MEDTECH$1.6B$677.0M$647.0M$728.0M$786.0M$714.0M

Sales to customers (Note 9)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Innovative Medicine$14.3B$13.9B$15.2B$15.6B$15.8B$15.4B
MEDTECH$8.2B$8.0B$8.5B$8.4B$8.8B$8.6B

Selling, marketing and administrative expenses

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Innovative Medicine$3.3B$2.3B$2.8B$2.9B$3.5B$2.9B
MEDTECH$2.8B$2.7B$2.9B$2.8B$3.0B$2.9B

Indefinite-lived trademarks

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
MedTech————$1.7B—

Marketable Security, Realized Gain (Loss)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
MedTech—$50.0M$50.0M$50.0M$50.0M—

Restructuring

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medtech Ortho Franchise$33.0M$38.0M$38.0M$38.0M$38.0M—
Orthopaedics Restructuring Plan—$76.8M$76.8M$76.8M$76.8M—

Restructuring (Note 12)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
MEDTECH$93.0M$55.0M$100.0M$200.0M$200.0M$100.0M

Accrued Rebates Returns And Promotions

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Pharmaceutical$12.3B———$13.0B—